Show simple item record

dc.contributor.authorPolygenic Risk Score Task Force of the International Common Disease Alliance
dc.date.accessioned2022-01-21T00:31:10Z
dc.date.available2022-01-21T00:31:10Z
dc.date.issued2021-11
dc.identifier.issn1078-8956
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/332824
dc.description.abstractPolygenic risk scores (PRSs) aggregate the many small effects of alleles across the human genome to estimate the risk of a disease or disease-related trait for an individual. The potential benefits of PRSs include cost-effective enhancement of primary disease prevention, more refined diagnoses and improved precision when prescribing medicines. However, these must be weighed against the potential risks, such as uncertainties and biases in PRS performance, as well as potential misunderstanding and misuse of these within medical practice and in wider society. By addressing key issues including gaps in best practices, risk communication and regulatory frameworks, PRSs can be used responsibly to improve human health. Here, the International Common Disease Alliance's PRS Task Force, a multidisciplinary group comprising expertise in genetics, law, ethics, behavioral science and more, highlights recent research to provide a comprehensive summary of the state of polygenic score research, as well as the needs and challenges as PRSs move closer to widespread use in the clinic.
dc.format.mediumPrint-Electronic
dc.publisherNature Research
dc.rightsAll Rights Reserved
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectAlleles
dc.subjectData Collection
dc.subjectDisease Progression
dc.subjectGenetic Predisposition to Disease
dc.subjectGenome, Human
dc.subjectHumans
dc.subjectMultifactorial Inheritance
dc.subjectPhenotype
dc.subjectRecurrence
dc.subjectRisk Factors
dc.titleResponsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps.
dc.typeArticle
dc.date.updated2022-01-19T15:16:55Z
prism.endingPage1884
prism.issueIdentifier11
prism.publicationDate2021
prism.publicationNameNature Medicine
prism.startingPage1876
prism.volume27
dc.identifier.doi10.17863/CAM.80258
dcterms.dateAccepted2021-09-22
rioxxterms.versionofrecord10.1038/s41591-021-01549-6
rioxxterms.versionAM
dc.identifier.eissn1546-170X
rioxxterms.typeJournal Article/Review
pubs.funder-project-idEuropean Commission Horizon 2020 (H2020) Societal Challenges (101016775)
pubs.funder-project-idMedical Research Council (MR/L003120/1)
pubs.funder-project-idBritish Heart Foundation (RG/18/13/33946)
pubs.funder-project-idBritish Heart Foundation (None)
pubs.funder-project-idESRC (ES/T013192/1)
cam.issuedOnline2021-11-15
cam.orpheus.success2022-01-20 - Embargo set during processing via Fast-track
cam.depositDate2022-01-19
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement
rioxxterms.freetoread.startdate2022-05-15


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record